NCT02616055

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Kadmon Corporation, LLC · Industry
• Sex: All
• Age: 18 Years – 62 Years
• Healthy volunteers: Not accepted

Summary

Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.

Conditions

• Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

Type	Name	Description
DRUG	tesevatinib

Timeline

• Start date: 2015-12-25
• Primary completion: 2016-12-21
• Completion: 2016-12-21
• First posted: 2015-11-26
• Last updated: 2022-05-25

Locations

6 sites across 1 country: United States